The Potential of Dendritic-Cell-Based Vaccines to Modulate Type 3 Innate Lymphoid Cell Populations

Lily Chan; Yeganeh Mehrani; Jessica A Minott; Byram W Bridle; Khalil Karimi

doi:10.3390/ijms24032403

The Potential of Dendritic-Cell-Based Vaccines to Modulate Type 3 Innate Lymphoid Cell Populations

Int J Mol Sci. 2023 Jan 26;24(3):2403. doi: 10.3390/ijms24032403.

Authors

Lily Chan¹, Yeganeh Mehrani^{1

2}, Jessica A Minott¹, Byram W Bridle^{1

3}, Khalil Karimi¹

Affiliations

¹ Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G2W1, Canada.
² Department of Clinical Science, School of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad 9177948974, Iran.
³ ImmunoCeutica Inc., Cambridge, ON N1T 1N6, Canada.

Abstract

Dendritic cell (DC) vaccines are a type of immunotherapy that relies on the communication of DCs with other aspects of the immune system. DCs are potent antigen-presenting cells involved in the activation of innate immune responses and education of adaptive immunity, making them ideal targets for immunotherapies. Innate lymphoid cells (ILCs) are relatively newly identified in the field of immunology and have important roles in health and disease. The studies described here explored the communications between type 3 ILCs (ILC3s) and DCs using a murine model of DC-based vaccination. Local and systemic changes in ILC3 populations following the administration of a DC vaccine were observed, and upon challenge with B16F10 melanoma cells, changes in ILC3 populations in the lungs were observed. The interactions between DCs and ILC3s should be further explored to determine the potential that their communications could have in health, disease, and the development of immunotherapies.

Keywords: communication; dendritic cell (DC); innate; type 3 innate lymphoid cell (ILC3).

MeSH terms

Adaptive Immunity
Animals
Dendritic Cells
Immunity, Innate
Lymphocytes*
Mice
Vaccines*

Substances

Vaccines

Grants and funding

Operating funds were provided by a Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant (#436264) and an Innovation Grant that was jointly funded by the Canadian Cancer Society Research Institute (#705965) and the Canadian Institutes of Health Research–Institute of Cancer Research (#160399) (both awarded to B.W.B.). Stipend funding was provided by an Ontario Graduate Scholarship (OGS), NSERC Postgraduate Scholarship—Doctoral, and Ontario Veterinary College Scholarship (L.C.).